F2D Medical

F2D Medical’s Thermodiag has undergone extensive R&D over four years, including more than 15,000 hours of data acquisition. Clinical results support reliable non-invasive measurement and prediction of core body temperature in adults. The system aids diagnostics, therapy selection/timing (“chronotherapy”), infection risk prevention/monitoring, and supports both hospital-based and home-based patient management. Three phases of clinical trials completed on 306 subjects; two pre-clinical trials underway as of late 2024/early 2025. The product is in use on volunteers since November 2020. Commercialization has begun or is imminent as the company markets the device at major healthcare conferences. Clinical trial identifier: NCT04311268.